Skip to main content

Catalyst Calendar

Scope

Mon, Aug 10, 2026

1 updates
SANA
4:05 PM

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data,

Presentation / AbstractEASD presentation Fri, Oct 2, 2026sana.com

Mon, Jul 13, 2026

1 updates
SANA
8:00 AM

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025 Seminal Study Successfully Achieved Primary and Secondary Endpoints, Demonstrating that Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by

Trial ResultsNEJM publication of long-term data Mon, Jul 13, 2026, 8:00 AM EDTsana.com

Wed, Jul 1, 2026

1 updates
SANA
9:00 AM

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study

Presentation / AbstractSymposium presentation Fri, Oct 2, 2026, 9:10 AM CESTsana.com